About Neil Flanzraich
Neil Flanzraich is an executive chairman of the board of directors at Alzheon.
Neil Flanzraich first appears on SEC filings in 2018.
Experience
This experience comes from Neil Flanzraich's profile and from SEC filings. For roles taken from filings, the years are when the filings name Neil Flanzraich in the role, so the role may have started earlier or lasted longer.
CI
Cantex Pharmaceuticals, Inc. Current
Executive Chairman
2013 – Present
Alzheon, Inc.
Executive Chairman of the Board of Directors
2018 – 2026 · Framingham, MA
Develops investigational medicines for people with Alzheimer’s and other neurodegenerative disorders.
IP
Ivax Pharmaceuticals
Vice Chairman and President
1998 – 2006
NI
North American Vaccine, Inc.
Chairman of the Board
1995 – 2000
HE
Heller Ehrman
Chairman of the Life Sciences Legal Practice Group
1995 – 1998
SC
Syntex Corporation
Senior Vice President, General Counsel and Member of the Operating and Executive Committees
1981 – 1994
Key Colleagues at Startups
The people Neil Flanzraich works with at each company, as listed on that company's latest Form D.
Alzheon, Inc. · Form D, Sep 10, 2026
Christopher Dunn
Director
Diane Jorkasky, M.D.
Director
JD
John Hey, Ph.D.
Chief Scientific Officer
SD
Susan Abushakra, M.D.
Chief Medical Officer
MS
Muneer Satter
Director
Jordan Heller
Director
AM
Aidan Power, MRCPsych
Chief Development Officer
Gino Santini
Director
Kenneth Mace
Chief Financial Officer
MD
Martin Tolar, M.D., Ph.D.
Founder, President & CEO, director
Adem Albayrak
Chief Data & AI Officer